MAM
MARS Petcare launches TEMPTATIONS™, the world’s most irresistible cat treat, in India
Mumbai: MARS Petcare, the world’s leading pet food company, is launching the internationally-recognised cat treat brand TEMPTATIONS™ in India. The product is recognised worldwide as a fun, playful treating experience for cats and their owners. TEMPTATIONS™ will be available in more than 180 cities from the 8th of December 2020.
TEMPTATIONS™ Treats are nutritionally balanced snacks that are crunchy on the outside and with delicious filling in the centre. These treats provide all the right nutrients for cats in the amounts needed. Each treat has about two calories and it is recommended that owners feed up to 15 treats per 4.5 kg of the cat's body weight, but it is best to consult a veterinarian regarding your cat’s weight management.
Ganesh Ramani, General Manager, MARS Petcare India, said: “Along with a balanced diet, cat treats strengthen the bond between cats and pet parents. So, we are very excited to launch TEMPTATIONS™ in India. These treats are healthy with the goodness of proteins, vitamins and minerals and have only 2 calories each, so you can indulge your cat without worry. They are also a great way to strengthen your bond with your cat, who’re curious by nature and will come running to you every time they hear the sound of the treat packet opening. We hope to make the world a better place for all cats and their owners, and we know that pet enjoyment and nutrition are key to the pet parent’s choice of food or treats.”
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
